Rodman & Renshaw Downgrades Arena Pharmaceuticals (ARNA) to Market Underperform
Tweet Send to a FriendGet Alerts ARNA Hot Sheet
Price: $7.99 +0.13%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 33 | New: 12
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 33 | New: 12
Trade ARNA Now!
Rodman & Renshaw downgrades Arena Pharmaceuticals (Nasdaq: ARNA) from Market Perform to Market Underperform. PT $1.
To see all the upgrades/downgrades on shares of ARNA, visit our Analyst Ratings page.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
To see all the upgrades/downgrades on shares of ARNA, visit our Analyst Ratings page.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
You May Also Be Interested In
- Goldman Sachs Downgrades Thoratec (THOR) to Neutral
- Susquehanna Downgrades The Children's Place (PLCE) to Neutral
- JMP Securities Downgrades MicroStrategy (MSTR) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Rodman & Renshaw
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
